Literature DB >> 396701

Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 396701     DOI： 10.1016/0041-3879(79)90001-1

Source DB:  PubMed          Journal:  Tubercle        ISSN： 0041-3879


× No keyword cloud information.
  16 in total

Review 1.  Current medical treatment for tuberculosis.

Authors:  Edward D Chan; Michael D Iseman
Journal:  BMJ       Date:  2002-11-30

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

3.  Coadministration of Allopurinol To Increase Antimycobacterial Efficacy of Pyrazinamide as Evaluated in a Whole-Blood Bactericidal Activity Model.

Authors:  Claire M Naftalin; Rupangi Verma; Meera Gurumurthy; Qingshu Lu; Matthew Zimmerman; Benjamin Chaik Meng Yeo; Kin Hup Tan; Wenwei Lin; Buduo Yu; Véronique Dartois; Nicholas I Paton
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

4.  The case for short-course chemotherapy of pulmonary tuberculosis.

Authors:  J H Angel
Journal:  Drugs       Date:  1983-07       Impact factor: 9.546

5.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

Review 6.  Short-course therapy for tuberculosis.

Authors:  M Aquinas
Journal:  Drugs       Date:  1982-08       Impact factor: 9.546

7.  Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.

Authors:  Kwok-Chiu Chang; Chi-Chiu Leung; Wing-Wai Yew; Eric Chung-Ching Leung; Wai-Man Leung; Cheuk-Ming Tam; Ying Zhang
Journal:  Antimicrob Agents Chemother       Date:  2012-08-06       Impact factor: 5.191

Review 8.  Drug therapy in spinal tuberculosis.

Authors:  S Rajasekaran; Gaurav Khandelwal
Journal:  Eur Spine J       Date:  2012-05-12       Impact factor: 3.134

Review 9.  Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Sarah Royce; Pai Madhukar; William Burman; Andrew Vernon; Christian Lienhardt
Journal:  PLoS Med       Date:  2009-09       Impact factor: 11.069

Review 10.  Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman
Journal:  PLoS Med       Date:  2009-09-15       Impact factor: 11.069
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.